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The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multicentre, prospective, randomized,
double-blind, parallel-group study designed to compare the effects of candesartan cilexetil and placebo in
elderly patients with mild hypertension. The primary objective of the study is to assess the effect of
candesartan cilexetil on major cardiovascular events. The secondary objectives of the study are to assess
the effect of candesartan cilexetil on cognitive function and on total mortality, cardiovascular mortality,
myocardial infarction, stroke, renal function, hospitalization, quality of life and health economics. Male
and female patients aged between 70 and 89 years, with a sitting systolic blood pressure (SBP) of 160–
179 mmHg and/or diastolic blood pressure (DBP) of 90–99 mmHg, and a Mini-Mental State Examination
(MMSE) score of 24 or above, are eligible for the study. The overall target study population is 4000
patients, at least 1000 of whom are also to be assessed for quality of life and health economics data. After
an open run-in period lasting 1–3 months, during which patients are assessed for eligibility and those who
are already on antihypertensive therapy at enrolment are switched to hydrochlorothiazide 12.5 mg o.d.,
patients are randomized to receive either candesartan cilexetil 8 mg once daily (o.d.) or matching placebo
o.d. At subsequent study visits, if SBP remains>160 mmHg, or has decreased by<10 mmHg since the
randomization visit, or DBP is>85 mmHg, study treatment is doubled to candesartan cilexetil 16 mg o.d.
or two placebo tablets o.d. Recruitment was completed in January 1999. At that time 4964 patients had
been randomized. All randomized patients will be followed for an additional 2 years. If the event rate is
lower than anticipated, the follow-up will be prolonged. Key words: mild hypertension, elderly, candesartan
cilexetil, cardiovascular events, cognitive function.
INTRODUCTION
The proportion of the elderly people in the general
population, and particularly of very elderly people, is
increasing in most industrialized countries [1]. This trend
is expected to continue well beyond the year 2000,
leading to a greater prevalence of cardiovascular and
cerebrovascular disease, which increase considerably
with age. Recent data from a worldwide study show that
cardiovascular and cerebrovascular disease are already
the leading causes of death and disability in the
industrialized world [2].
Hypertension is one of the major risk factors for both
coronary heart disease and stroke, which have been shown
to increase by around five-fold and ten-fold, respectively,
with increasing diastolic blood pressure (DBP) from
76 mmHg to 105 mmHg [3]. Cerebrovascular disease, as
manifested by stroke and ischaemic white matter changes,
results in varying degrees of brain dysfunction, including
dementia, and represents a chronic health problem with
important personal, social and economic implications. A
history of atherosclerosis alone, excluding the effects of
age and education, has also been shown to be associated
with decreased cognitive performance [4].
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Prevention of cardiovascular and cerebrovascular
complications
The beneficial effects of treating hypertension have been
documented in a number of studies. In a meta-analysis of
several, prospective randomized intervention trials invol-
ving nearly 48 000 patients, a DBP reduction of 5–
6 mmHg was found to decrease the risk of stroke by 38%
and heart disease by 16% [5]. Four major studies have
also shown that stroke morbidity and mortality in the
elderly can be significantly reduced with antihypertensive
therapy: the Systolic Hypertension in the Elderly Program
(SHEP) [6] in the USA, the Swedish Trial in Old Patients
with Hypertension (STOP-Hypertension) [7], the British
Medical Research Council (MRC) study in older adults
[8] and the Systolic Hypertension in Europe (Syst-Eur)
study [9]. In all of these studies, the entry systolic blood
pressure (SBP) was relatively high. However, the value of
antihypertensive treatment in elderly patients with DBP in
the range 90–99 mmHg remains an open issue, since DBP
at entry in both the STOP and MRC trials was above these
values, and the SHEP and Syst-Eur studies specifically
recruited patients with isolated systolic hypertension.
The impact of hypertension on cognitive function and
dementia
Hypertension is generally recognized to be a major risk
factor for the development of ischaemic white matter
lesions [10, 11], as well as stroke [12]. Old age, and
especially very old age, is associated with an increased
risk of dementia [13]. More than 60 diseases are
associated with the syndrome of dementia, the most
common being Alzheimer’s disease (AD) and vascular
dementia (VAD) [14]. In a recent study, VAD was found
to be more common than previously assumed [15].
Although all the risk factors for VAD have yet to be
identified, it is obvious that arterial hypertension plays an
important role [10]. In a longitudinal study of nearly 1000
elderly Swedish men, there was an inverse relationship
between DBP at 50 years of age and cognitive function at
70 years of age [16], as determined by psychometric
testing and use of the Mini-Mental State Examination
(MMSE) [17, 18]. In a further Swedish study, a significant
link was found between the presence of high SBP and
DBP at age 70 years and the development of dementia
10–15 years later [19].
The risk of developing dementia increases at least nine-
fold after a stroke [20, 21]. Furthermore, ischaemic white
matter lesions have also been linked to AD and to VAD
[10]. Other cardiovascular disorders, such as myocardial
infarction [22, 23] and generalized atherosclerosis [24],
may also increase the risk of developing dementia.
Rationale for proposed study
At the time of planning SCOPE, an analysis of nine
prospective observational studies suggested that there was
no apparent threshold DBP below which the risk of stroke
was not continuously reduced [25]. The results of the
recently completed Hypertension Optimal Treatment
(HOT) Study indicated that the lowest risk of stroke
(fatal and non-fatal) was achieved at a DBP of
<85 mmHg [26]. However, HOT was not a study in the
elderly, since in this cohort the mean age was 62 years
and, furthermore, patients had a mean DBP of 105 mmHg
(3.4) at randomization.
An as yet unanswered question, is whether antihyper-
tensive treatment provides protection against stroke in
patients with an initial DBP of 90–99 mmHg. In addition,
although the term “preventable senility” has been used
[27], there is no definitive evidence to show that lowering
of elevated blood pressure can reduce the incidence of
dementia. However, a subgroup analysis from the Syst-
Eur Study [28] showed that treatment of isolated systolic
hypertension with the long-acting calcium antagonist
nitrendipine reduced the incidence of dementia and AD
by 50%. These results further emphasize that treatment of
hypertension may be a potential way to prevent develop-
ment of dementia and cognitive decline in the elderly. A
clinical study to assess the effects of antihypertensive
drug treatment on major cardiovascular events and
cognitive function in elderly patients with mild hyperten-
sion is therefore warranted.
There may be a considerable benefit of antihyperten-
sive therapy in this group of patients, since there is a
continuum between dementia and cognitive impairment
in the elderly population [29]. Hence, even if treatment of
vascular risk factors results in only a small improvement
in the whole distribution of cognitive ability, it may lead
to a substantial reduction in the prevalence of overt
dementia [4, 29]. Furthermore, since hypertension and
other cardiovascular disorders are common in the elderly,
they may make a much greater contribution to the number
of cases of dementia than more infrequent disorders
associated with a higher risk [4, 29].
Rationale for using candesartan cilexetil
Angiotensin II type 1 (AT1) receptor blockers represent a
new class of antihypertensive agents. Unlike ACE-
inhibitors, AT1-receptor blockers do not inhibit the break-
down of bradykinin or other kinins, and this novel class of
drugs is not associated with a dry cough [30]. The excellent
tolerability and relative lack of contraindications of these
agents make them highly suitable for the treatment of
hypertension in the elderly. Moreover, AT1-receptor
blockers may help to maintain or even improve cognitive
function through mechanisms other than blood pressure
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(BP) reduction. In experimental models of cognitive
function, angiotensin II has been shown to impair
performance in learning and memory paradigms, which
appears to be the result of angiotensin II-induced inhibition
of acetylcholine release [31]. Animal studies have also
shown that treatment with the AT1-receptor blocker
losartan can improve cognitive performance [32]. There-
fore, it seemsplausible thatselectiveantagonistsfor theAT1
subtype of the angiotensin II receptor may represent a novel
approach for the treatment of cognitive disorders.
Candesartan cilexetil is an AT1-receptor blocker that
provides a dose-related antihypertensive effect in doses of
up to 16 mg [33]. Given once daily it results in a smooth
blood pressure reduction over the 24-h dosing interval. It
has also proven effective and well tolerated in elderly and
very old patients [34].
THE SCOPE STUDY
The Study on COgnition and Prognosis in the Elderly
(SCOPE) is a multicentre, prospective, randomized,
double-blind, parallel-group study designed to compare
the effects of candesartan cilexetil and placebo on
cardiovascular events and cognitive function in elderly
patients with mild hypertension. Based on data from the
STOP-Hypertension study [7], the overall target study
population is 4000 patients. This represents the calculated
number of patients required to detect a 23% difference
(with a power of 0.80 and a significance level of 0.05),
between the groups, in reduction in incidence of major
cardiovascular events over the study period, assuming a
starting DBP of 95 mmHg. Randomization was per-
formed centrally at the Coordinating Center at Sahl-
grenska University Hospital/O¨ stra, Go¨teborg, Sweden.
Objectives
The primary objective of the study is to assess the effect
of candesartan cilexetil on major cardiovascular events
(cardiovascular death, non-fatal myocardial infarction
and non-fatal stroke) in elderly patients with mild
hypertension.
The secondary objectives of the study are to assess the
effect of candesartan cilexetil on cognitive function, as
measured by the MMSE, and also on total mortality,
cardiovascular mortality, myocardial infarction, stroke,
renal function, hospitalization, quality of life and health
economics.
The influence of a number of variables on major
cardiovascular events and cognitive function will also be
investigated, as outlined in the listed objectives of
SCOPE, below.
1. Primary objective
a. to assess the effect of candesartan cilexetil on major
cardiovascular events (cardiovascular death, non-
fatal myocardial infarction and non-fatal stroke) in
elderly patients with mild hypertension.
2. Secondary objectives
a. to assess the effect of candesartan cilexetil on:
i) cognitive function as measured by the Mini
Mental State Examination (MMSE)
ii) total mortality
iii) cardiovascular mortality
iv) fatal and non-fatal myocardial infarction
v) fatal and non-fatal stroke
vi) impaired renal function (a doubling of S-
creatinine values compared with baseline)
vii) hospitalization
viii) quality of life
ix) health economics
3. Variables to be investigated for possible influence on
major cardiovascular events and cognitive function
a. age
b. gender
c. antihypertensive treatment at entry
d. previous myocardial infarction
e. previous stroke
f. diabetes mellitus (treated with diet or drugs) at
entry
g. smoking at entry
h. body mass index at entry
i. ECG signs of left ventricular hypertrophy at entry
j. hyperlipidaemia or treatment with lipid-lowering
drugs at entry
k. cognitive function (MMSE score) at entry
l. level of education.
Patients
The patients were recruited from participating centres in
15 different countries. Both treated and untreated
hypertensive patients could be enrolled. Male and female
patients aged between 70 and 89 years, with a sitting SBP
160–179 mmHg and/or DBP 90–99 mmHg, and an
MMSE score of 24 or above, were eligible for the study.
The inclusion and exclusion criteria are summarized in
the list below. When further inclusion of patients was
stopped in January 1999, 4964 patients had been
randomized.
1. Inclusion criteria
a. male or female, aged 70–89 years, with or without
antihypertensive treatment. If treated, both the
investigator and the patient should accept that the
antihypertensive medication is standardized to
HCTZ 12.5 mg o.d.
b. BP: systolic 160–179 mmHg or diastolic 90–
99 mmHg or both (mean of two measurements)
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after 5–10 min of rest in the sitting position, on two
consecutive occasions, separated by at least 14 days
c. MMSE score 24 or above on two consecutive
occasions, separated by at least 14 days
d. signed informed consent
2. Exclusion criteria
a. General:
i) need of antihypertensive treatment other than
HCTZ
ii) standing SBP< 140 mmHg after 2 min or a
history of symptomatic orthostatic hypotension
iii) sitting SBP 180 mmHg or DBP 100
mmHg
iv) secondary hypertension
v) stroke or myocardial infarction within 6
months prior to randomization
vi) decompensated congestive heart failure
vii) other serious concomitant diseases considered
by the investigator to affect survival during the
next 3–4 years
viii) alcoholism, drug abuse or any other problems
which may compromise compliance
ix) known hypersensitivity to the study drug
x) current participation in another clinical study
xi) known contraindications to HCTZ
xii) clinically significant impaired renal function
(serum creatinine 180 mmol/l for males and
140 mmol/l for females)
xiii) serum ASAT or ALAT more than three times
the upper limit of normal
b. Cognitive function:
i) obvious dementia, even if MMSE score
remains above 23
ii) current treatment with antidementia drugs
iii) conditions which preclude MMSE (e.g. illiter-
acy, poor eye sight, hearing impairment,
paralysis, aphasia or other speech disorders)
iv) vitamin B12 deficiency, untreated or treated
less than 12 months
v) hypothyroidism, untreated or treated less than
12 months
vi) neurosyphilis or AIDS
vii) severe brain disorder that may interfere with
cognitive function
viii) severe depression within the last 12 months or
psychotic disorder
ix) psychopharmacological treatment (instituted
within the last 6 months)
Overall study design
After an open run-in period (1–3 months) which included
the initial (enrolment) and qualifying visits, patients were
randomized in a double-blind fashion to receive either
candesartan cilexetil 8 mg once daily (o.d.) or a matching
placebo tablet (o.d.). After all patients had been
randomized, follow-up will continue for 2 further years
(Fig. 1). The follow-up may be prolonged if the event rate
is lower than anticipated.
Enrolment visit. At this initial visit, the patients’
eligibility was checked together with the absence of
exclusion criteria. All patients on current anti-
hypertensive therapy had their medication standardized
to hydrochlorothiazide (HCTZ) 12.5 mg o.d. after an
appropriate reduction of prior treatment.
First qualifying visit. All patients considered eligible
for the study at the enrolment visit were asked to
return after at least 14 days, when repeat BP, heart rate
(HR) and MMSE assessments were carried out. For
patients who fulfilled the BP and MMSE inclusion
criteria, this visit was regarded as the first qualifying
visit. All patients (whether or not fulfilling the
inclusion criteria) were asked to return for a second
visit 14 days later and thereafter at 14-day intervals
until both BP and MMSE inclusion criteria were met
on two consecutive visits.
Second qualifying/randomization visit. If inclusion
criteria were fulfilled at the second consecutive visit, a
medical history was recorded and patients underwent a
physical examination, ECG, laboratory analysis, and
any adverse events were recorded. Patient data were
sent by fax to the Coordinating Center, where patients
fulfilling all of the inclusion criteria and none of the
exclusion criteria were randomized to receive either
candesartan cilexetil 8 mg o.d. or placebo o.d. The
investigators were informed about treatment allocation
in the form of patient number by return fax. The
following variables were taken into account when
randomizing patients: age, gender, previous myocardial
infarction, atrial fibrillation, previous stroke, treatment
with non-steroid anti-inflammatory drug or acetyl-
salicylic acid, MMSE score, level of education, body
mass index, chronic treatment with lipid-lowering
drugs, chronic treatment with psychopharmacological
therapy, previously treated with antihypertensive drugs,
smoking and language area.
Study visits. Patients were asked to return for the first
study visit 1 month after the randomization visit and
Fig. 1. Overall study design.
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then for a second visit 3 months after the randomization
visit. Thereafter, the patients are scheduled to be
followed regularly on a 6-month basis until the close of
the study. Extra visits may be performed according to
medical need.
Treatment schedule
After initial randomization to candesartan cilexetil 8 mg
o.d. or corresponding placebo o.d., patients whose SBP
remains >160 mmHg or has decreased by<10 mmHg
since the randomization visit, or whose DBP is
>85 mmHg will have their treatment doubled to two
tablets (candesartan cilexetil 16 mg o.d. or two matching
placebo tablets o.d.). If, at subsequent visits, a patient’s
SBP remains160 mmHg or the DBP 90 mmHg, it is
recommended that additional antihypertensive medica-
tion is given. Recommended add on treatment is HCTZ
12.5 mg. The addition of other AT1-receptor blockers or
ACE-inhibitors is not allowed as antihypertensive treat-
ment. This and any other treatment that is considered
necessary for the patient’s welfare may be given at the
discretion of the investigator.
Efficacy variables
Cardiovascular. At all visits, SBP, DBP and HR are
measured in the sitting position after 5–10 min of rest.
Three recordings of BP are made, at least 1 min apart.
The mean SBP/DBP is calculated from the last two
measurements. A 12-lead resting ECG was recorded at
the randomization visit and after 1 month.
Cognition. Cognitive function is evaluated by using
the MMSE, which is an instrument that has been
widely used to screen for cognitive function in
different populations. After recording of BP and HR,
an MMSE is performed at each visit, except after 1
and 3 months. As far as possible, the test is performed
by the same person throughout the study. As the
application of the MMSE differs widely, a standardized
protocol for the use of the MMSE in this study was
developed after discussions among members of the
Steering Committee.
Quality of life. Two standard quality of life question-
naires (the Psychological General Well-Being Index and
the Subjective Symptom Assessment Profile) and one
utility index are used to assess quality of life at the pre-
selected participating centres. These assessments are
made at the randomization visit (baseline questionnaire)
and after 6, 12 and 24 months of treatment. The
questionnaires are administered according to a standard-
ized procedure and completed by the patients them-
selves during the visit to the clinic.
Health economics. Healthcare resource utilization
data are collected in participating centres at each visit.
Some clinical data will also be used for the economic
analyses.
Definition of events
Clinical events. Clinical events are divided into three
categories:
1. cardiovascular (cardiovascular death, non-fatal myo-
cardial infarction and non-fatal stroke);
2. non-cardiovascular deaths;
3. significant cognitive decline (a reduction in MMSE
score of 4 points compared with the randomization
visit score).
The occurrence of a suspected clinical event is recorded
on the Serious Adverse Event/Clinical Event form. This
information together with additional documentation (such
as hospital records, ECG tracings, CT scan reports, etc.)
will form the basis on which the Independent Clinical
Event Committee will validate the reported events.
Adverse events. Any adverse events, including serious
adverse events, are recorded in connection with study
visits.
Time schedule
Recruitment to SCOPE began in March 1997 and was
completed in January 1999. As noted above, all
randomized patients are scheduled for a follow-up period
of at least 2 years. If the event rate is lower than
anticipated (approximately 40 major cardiovascular
events per 1000 patient years), the follow-up may be
prolonged. Alternatively, the study may be terminated if
recommended by the Independent Safety Committee.
Ethics
Informed consent, in accordance with the Declaration of
Helsinki, was obtained from all patients prior to entering
the study. Good clinical practice is observed and the study
protocol was approved by the Ethics Committee con-
cerned before enrolment of patients into the study.
Organization
An Executive Committee is responsible for the planning
and conduct of the study and reports to the Steering
Committee. In addition to the Chairmen, Secretary and
Statistician, the Executive Committee1 consists of three
representatives from different countries as well as non-
voting representatives from the sponsoring pharmaceu-
tical company.
1 Executive Committee members: L. Hansson, H. Lithell, I. Skoog,
D. Elmfeldt, B. Olofsson (Sweden), P. Trenkwalder (Germany), A.
Hofman (The Netherlands), A. Zanchetti (Italy).
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The Steering Committee2 comprises the members of
the Executive Committee, together with one or two
representatives from each participating country. The
chairpersons, secretary and statistician are the same in
both committees. The Steering Committee is in charge of
approval of the protocol and amendments, organization,
data handling and general conduct of the study.
An Independent Safety Committee3, comprising three
members who are independent of other parts of the study
organization, is supervising the evolution of the study,
especially with respect to the occurrence of clinical
events. It is also empowered to advise the Steering
Committee on study termination.
An Independent Clinical Event Committee4, consisting
of three members who are independent of other parts of
the study organization, evaluates and classifies all
reported clinical events, without knowledge of the study
group to which the patient belongs.
Study monitors have been appointed in each of the
participating countries to have regular contact with the
investigational sites in order to confirm acceptability of
facilities, adherence to the study protocol, accurate
recording of data and to provide information and support
to the investigators.
The SCOPE5 trial is sponsored by AstraZeneca.
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